Drug Interaction Study to Evaluate the Effect of DUR-928 on the Pharmacokinetics of a Single Oral Dose of Midazolam in healthy participants.

Trial Profile

Drug Interaction Study to Evaluate the Effect of DUR-928 on the Pharmacokinetics of a Single Oral Dose of Midazolam in healthy participants.

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs DUR 928 (Primary) ; DUR 928 (Primary) ; Midazolam
  • Indications Acute kidney injury; Fatty liver; Liver disorders; Non-alcoholic steatohepatitis; Psoriasis; Stroke
  • Focus Pharmacokinetics
  • Acronyms C928-018
  • Sponsors DURECT Corporation
  • Most Recent Events

    • 08 Aug 2017 According to a DURECT Corporation media release, data from this trial will included in upcoming INDs submitted to the US FDA.
    • 14 Jul 2017 Status changed from not yet recruiting to completed.
    • 25 Apr 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top